

ORAMED PHARMACEUTICALS INC.  
Form 8-K  
September 03, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): September 3, 2015

**ORAMED PHARMACEUTICALS INC.**  
(Exact name of registrant as specified in its charter)

**DELAWARE**                      **001-35813**      **98-0376008**  
(State or Other Jurisdiction) (Commission (IRS Employer  
of Incorporation)              File Number) Identification No.)

**Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel**      **91390**  
(Address of Principal Executive Offices)                                      (Zip Code)

**+972-2-566-0001**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01. OTHER EVENTS.**

On September 3, 2015, Oramed Pharmaceuticals Inc. (the “Company”), and its wholly-owned subsidiary (the “Subsidiary”), agreed to extend for 45 days the no-shop period contained in the non-binding Letter of Intent (“LOI”) that was signed with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd. (together, “Sinopharm-HLST”) on July 3, 2015. The 45 day extension is intended to allow sufficient time for the parties to conclude the definitive agreements.

**Warning Concerning Forward Looking Statements**

This Current Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the 45 days extension of the LOI with Sinopharm-HLST is intended to allow sufficient time for the conclusion of definitive agreements between the parties. However, the LOI is non-binding and subject to negotiation; accordingly, the conclusion of definitive documentation may be delayed or may not occur. For these reasons, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORAMED  
PHARMACEUTICALS  
INC.

By: /s/ Nadav Kidron  
Name: Nadav Kidron

September 3, 2015 Title: President and CEO